|
Market
Equities Research - Market Bulletin
January 3, 2022 1:30 AM UTC
Eyes on DIAGNOS Inc., Multiple Catalysts Converging, Major Players
Positioning
-
The eyes not only allow us to see, they also have something to
say; the blood vessels at the back of the eye (the retina
vasculature) are closely connected to your health and can
indicate underlying problems.
-
Please note the context in terms
of size of entities actively engaged with DIAGNOS to integrate
its technology into their business.
|
Share data, Capitalization, & Corporate info
Shares Outstanding:
~69.12 million
Recently Traded:
~CDN$0.34/share (TSX-V:
ADK)
52 Week High/Low:
$0.77 / 0.33
Current Market Capitalization:
~$24 million CDN
Corporate Website:
www.DIAGNOS.ca |
 |
DIAGNOS Inc. (TSX-V: ADK) (OTCQB:
DGNOF) (Frankfurt: 4D4) is a Software as a Service (SaaS)
provider that pioneered 'Computer Assisted Retinal Analysis’ (CARA),
a machine assisted learning technology that detects and classifies
serious medical conditions in patients with diabetes or
cardiovascular issues from an image of the back of the eye; diabetic
retinopathy, hypertension retinopathy, stroke, AMD, glaucoma.
DIAGNOS is now making ground-breaking moves as the clear leader into
high-potential markets.
In-short, DIAGNOS Inc. is just one strong news release away from
ripping above $1/share entering 2022. Below is a sampling of
market insight and happenings currently in development by DIAGNOS
offering major near-term upward share price revaluation potential;
Cardiovascular Market:
DIAGNOS' Stroke Predictor CARA platform application began clinical
trials on Dec. 6, 2021 with CommonSpirit Health Research Institute,
the 2nd largest health service provider in the USA (~137
hospitals and >1,000 clinics, in 21 states). NOTE: As news of
progress materializes on this front, look for shares of TSX-V: ADK
to respond well to reflect the enormous upside potential. Success in
early detection of cardio vascular issues in such a non-invasive
manner for the patient could quickly result in the DIAGNOS CARA
platform being a go-to service in a massive market place that
currently spends over half-a-trillion-$ a year in drugs and services
for cardiovascular and stroke issues.
CONTEXT takeaway: ”the 2nd largest health service provider in
the USA.”
Eyecare & Wellness Markets:
Leveraging DIAGNOS’ proven ability to screen for diabetic
retinopathy and more, eyecare stores appear to now be maturing into
Point of Care wellness diagnostic centers using DIAGNOS’s
technology. Look for related news announcements and deployment
rollouts to accelerate. In fact, Essilor Luxottica (symbol EL on
Euronex – the world’s largest eyecare company with ~18,000
locations) has a
MoU signed with DIAGNOS and is actively in negotiations on three
transaction points; 1) Deployment/access to DIAGNOS’ existing CARA
platform, 2) development of DIAGNOS technology into Essilor’s line
of fundus camera, 3) access to future applications of CARA as they
rollout.
CONTEXT takeaway: “the world’s largest eyecare company with
~18,000 locations.”
Also on this same front look for many other industry participants to
embrace DIAGNOS’ technology. New Look (with 407 locations in Canada)
signed on for CARA platform roll-out recently.
Additionally, DIAGNOS is currently assisting in roll-outs for
numerous medical facilities and government screening programs
globally.
DIAGNOS Inc. appears to possess exceptional risk-reward metrics
for investors establishing a long position now; ADK.V only has
69.12 million shares outstanding, there are very little warrants
left, and insiders & family office own ~40% of the outstanding
shares. DIAGNOS:
● is debt free,
● has money in the bank,
● has an untapped C$2 million government credit line if needed,
● has a high-margin SaaS model (it only costs ~4 cents to process an
image that it charges between ~C$5 - $10),
● is expected to be cash flow positive (based on solid contracts
in-hand) in the coming fiscal year,
● has numerous new business prospects in discussion now, and
● is expected to see rapid revenue growth.
Figure 1. (above) CARA (Computer Assisted
Retinal Analysis) Artery Vein (AV) Ratio analysis in action and retinal images
Figure 2. (Above) Revenue
generating medical applications - Product
pipeline.
DIAGNOS
Inc. received its first institutional coverage from the independent
investment bank / advisory / equity research firm Echelon Capital
Markets, its current rating is 'Top Pick', 'Speculative BUY' with a
near-term (12 month) target price per common share of DIAGNOS of
$1.55 Canadian (or in US dollars: USD$1.23 or in Euros: €1.09)
--
click here
to view full copy of their latest report. The original initiating
report was exceptionally thorough (~40 pages), the analyst contacted
multiple industry participants, and recently (November-2021) sat
down for an
interview
[running time 32 min. Youtube] on his reasoning for making it a top
pick entering 2022. Note, the analyst share price target is based on
the DIAGNOS’ CARA Platform that is currently in use and does not
include progress on the Stroke Predictor application that is the
subject of clinical trial news – needless
to say a much higher share price target is justified if success in
the Stroke Predictor clinical trial is demonstrated.
The following
URLs have been identified for further DD on DIAGNOS Inc.:
Company website:
http://www.diagnos.ca
SEDAR:
https://sedar.com/DisplayProfile.do?lang=EN&issuerType=03&issuerNo=00003037
Insider activity:
https://www.canadianinsider.com/node/7?menu_tickersearch=ADK+%7C+Diagnos
Recent Technology Journal Review:
https://technologymarketwatch.com/adk.htm
# #
This bulletin may contain
forward-looking statements regarding future events that involve risk and
uncertainties. Readers are cautioned that these forward-looking statements are
only predictions and may differ materially from actual events or results.
Articles, excerpts, commentary and reviews herein are for information purposes
and are not solicitations to buy or sell any of the securities mentioned.
Contact information:
Fredrick William, BaEc.
Market Equities Research Group
f.william@marketequitiesresearch.com
|
3